The goal of the Center for Investigational Therapeutics (CIT) laboratory program is to identify clinical candidate compounds as possible cancer-fighting agents to be considered for Phase I (first-in-man) clinical trials.
Researchers with the CIT work to discover new agents that can be developed into drugs. Chemists in our laboratory discover and develop compounds they believe can be used to target cancer cells. Our team can screen thousands of experimental compounds each year using both cell and tumor-based assays.
Our skilled researchers use cutting-edge techniques, such as lead compound identification and proof-of-mechanism studies, to rapidly advance compounds from discovery to clinical candidates. Our team has years of experience with approved anticancer agents and understands the efficacy and toxicity profiles for approved chemotherapeutics. This allows detailed evaluation of novel agents in combination with standard therapeutic courses of therapy.
Features of the preclinical program fall under two general categories:
- Computational and medicinal chemistry; including computer-aided drug design
- Cancer biology; including assay development, screening, biomarker identification and in vivo models for preclinical efficacy and imaging studies
Our laboratory and clinical teams have been involved in developing some of the most important cancer drugs used today.